July 13, 2015

National Comprehensive Cancer Network (NCCN Compendium®)
Joan McClure, MS, Sr. Vice President, Clinical Information & Publications
275 Commerce Drive, Suite 300
Fort Washington, PA 19034

Dear Ms. McClure,

The enclosed materials are being provided for your information in reference to the denosumab NCCN Compendium® monograph regarding new data recently made available on the adjuvant use of denosumab in postmenopausal patients with early hormone receptor-positive breast cancer receiving treatment with aromatase inhibitors.

Enclosed, please find the following:

- Summary of Request
- Prolia® (denosumab) US Prescribing Information, Amgen Inc. (v9, 02/2015)
- Prolia® (denosumab) US Medication Guide, Amgen Inc. (v8, 02/2015)

Amgen recommends the use of its products only in accordance with the Food and Drug Administration (FDA)-approved prescribing information (package insert). Please refer to the Prolia® (denosumab) full prescribing information included in this submission for approved product labeling and important safety information.

Should you have any questions or require additional materials, please feel free to contact me directly at (805) 447-3464. Thank you in advance for your prompt attention to this matter.

Sincerely,

Eleonora Ford, PhD
Director, Medical Information
eford@amgen.com
(805) 447-3464